In Vivo Readout of CFTR Function: Ratiometric Measurement of CFTR-Dependent Secretion by Individual, Identifiable Human Sweat Glands

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wine, Jeffrey J ^a,b   Char, Jessica E ^a   Chen, Jonathan ^a   Cho, Hyung ju ^a   Dunn, Colleen ^b   Frisbee, Eric ^a   Joo, Nam Soo ^a   Milla, Carlos ^b   Modlin, Sara E ^a   Park, Il Ho ^a   Thomas, Ewart A C ^a   Tran, Kim V ^a   Verma, Rohan ^a   Wolfe, Marlene H ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DYE; ISOPRENALINE; METHACHOLINE; MUSCARINIC RECEPTOR;

ADULT; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOSOL; FEMALE; HETEROZYGOSITY; HUMAN; IMAGING SOFTWARE; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; ORGAN SIZE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR BINDING; RECEPTOR BLOCKING; SENSITIVITY AND SPECIFICITY; SWEAT GLAND; SWEAT GLAND SIZE; SWEAT TEST; SWEATING;

ADRENERGIC BETA-AGONISTS; ADULT; AMINOPHYLLINE; ATROPINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROZYGOTE; HUMANS; INJECTIONS, INTRADERMAL; ISOPROTERENOL; MALE; METHACHOLINE CHLORIDE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; MUTATION; PURINERGIC P1 RECEPTOR ANTAGONISTS; SWEAT; SWEAT GLANDS; TIME FACTORS;

EID: 84886248186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077114     Document Type: Article

References (60)

1. Quinton PM, (2007) Cystic fibrosis: lessons from the sweat gland. Physiology (Bethesda) 22: 212-225.
2. Cooke RE, Gochberg SH, (1956) Physiology of the sweat gland in cystic fibrosis of the pancreas. Pediatrics 18: 701-715.
3. Di Sant'Agnese PA, Darling RC, Perera GA, Shea E, (1953) Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 12: 549-563.
4. Gibson LE, Cooke RE, (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23: 545-549.
5. Bishop MD, Freedman SD, Zielenski J, Ahmed N, Dupuis A, et al. (2005) The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet: 1-10.
6. Sato K, Sato F, (1984) Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest 73: 1763-1771.
7. Behm JK, Hagiwara G, Lewiston NJ, Quinton PM, Wine JJ, (1987) Hyposecretion of beta-adrenergically induced sweating in cystic fibrosis heterozygotes. Pediatr Res 22: 271-276.
8. Sato K, Sato F, (1988) Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes. J Lab Clin Med 111: 511-518.
9. Council NR (2011) Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press.
10. Trapnell BC, Chu CS, Paakko PK, Banks TC, Yoshimura K, et al. (1991) Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Natl Acad Sci U S A 88: 6565-6569.
11. Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG, (1992) Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest 90: 785-790.
12. Chu CS, Trapnell BC, Murtagh JJ Jr, Moss J, Dalemans W, et al. (1991) Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium [see comments]. Embo J 10: 1355-1363.
13. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG, (1993) Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 3: 151-156.
14. Luisetti M, Franco Pignatti P, (2003) Genetics of idiopathic disseminated bronchiectasis. Semin Respir Crit Care Med 24: 179-184.
15. Raman V, Clary R, Siegrist KL, Zehnbauer B, Chatila TA, (2002) Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 109: E13.
16. Cohn JA, Mitchell RM, Jowell PS (2004) The role of cystic fibrosis gene mutations in determining susceptibility to chronic pancreatitis. Gastroenterol Clin North Am 33: 817-837, vii.
17. Cohn JA, Neoptolemos JP, Feng J, Yan J, Jiang Z, et al. (2005) Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat 26: 303-307.
18. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, et al. (1995) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332: 1475-1480.
19. Dohle GR, Veeze HJ, Overbeek SE, van den Ouweland AM, Halley DJ, et al. (1999) The complex relationships between cystic fibrosis and congenital bilateral absence of the vas deferens: clinical, electrophysiological and genetic data. Human reproduction 14: 371-374.
20. Ramsey BW, (2007) Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps? Proc Am Thorac Soc 4: 367-369.
21. Welsh MJ, Smith AE, (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254.
22. Veeze HJ, Halley DJ, Bijman J, de Jongste JC, de Jonge HR, et al. (1994) Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. The Journal of clinical investigation 93: 461-466.
23. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, et al. (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353: 1443-1453.
24. Guo X, Pace RG, Stonebraker JR, Commander CW, Dang AT, et al. (2011) Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC. PLoS One 6: e25452.
25. Joo NS, Wu JV, Krouse ME, Saenz Y, Wine JJ, (2001) Optical method for quantifying rates of mucus secretion from single submucosal glands. Am J Physiol Lung Cell Mol Physiol 281: L458-468.
26. Wine JJ, Joo NS, Choi JY, Cho HJ, Krouse ME, et al. (2011) Measurement of fluid secretion from intact airway submucosal glands. Methods in molecular biology 742: 93-112.
27. Bates D (2007) Lme4: Linear mixed-effects models using S4 classes. R package. Vienna: R Foundation for Statistical Computing.
28. R_Development_Core_Team (2011) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
29. Altman DG, Bland JM, (1997) Statistics notes. Units of analysis. BMJ 314: 1874.
30. Andersen B (1990) Methodological errors in medical research: an incomplete catalogue Oxford: Blackwell Scientific Publications. 270 p.
31. Baayen RH (2008) Analyzing Linguistic Data A Practical Introduction to Statistics using R. Cambridge: Cambridge University Press.
32. Kuno Y (1956) Human Perspiration. Springfield IL Thomas.
33. Sato K, Sato F, (1981) Role of calcium in cholinergic and adrenergic mechanisms of eccrine sweat secretion. Am J Physiol 241: C113-120.
34. Sato K, Sato F, (1981) Pharmacologic responsiveness of isolated single eccrine sweat glands. Am J Physiol 240: R44-51.
35. Sato K, Sato F, (1983) Cholinergic potentiation of isoproterenol-induced cAMP level in sweat gland. Am J Physiol 245: C189-195.
36. Wilschanski M, Zielenski J, Markiewicz D, Tsui LC, Corey M, et al. (1995) Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 127: 705-710.
37. Knowles M, Gatzy J, Boucher R, (1981) Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305: 1489-1495.
38. Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, et al. (2004) Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 37: 385-392.
39. Choi JY, Joo NS, Krouse ME, Wu JV, Robbins RC, et al. (2007) Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. J Clin Invest 117: 3118-3127.
40. Lee RJ, Foskett JK, (2010) cAMP-activated Ca2+ signaling is required for CFTR-mediated serous cell fluid secretion in porcine and human airways. J Clin Invest 120: 3137-3148.
41. Lee RJ, Foskett JK, (2012) Why Mouse Airway Submucosal Gland Serous Cells Do Not Secrete Fluid in Response to cAMP Stimulation. The Journal of biological chemistry 287: 38316-38326.
42. Moran O, Zegarra-Moran O, (2005) A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 579: 3979-3983.
43. Suen YF, Robins L, Yang B, Verkman AS, Nantz MH, et al. (2006) Sulfamoyl-4-oxoquinoline-3-carboxamides: Novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 6: 537-540.
44. Cai Z, Taddei A, Sheppard DN, (2006) Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. J Biol Chem 281: 1970-1977.
45. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine 365: 1663-1672.
46. Sanders DB, Farrell PM, (2012) Transformative mutation specific pharmacotherapy for cystic fibrosis. BMJ 344: e79.
47. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, et al. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-1130.
48. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, et al. (2011) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax.
49. Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, et al. (2007) In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 5: 5.
50. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430-444.
51. Du M, Keeling KM, Fan L, Liu X, Kovacs T, et al. (2006) Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 84: 573-582.
52. Howard M, Frizzell RA, Bedwell DM, (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations [see comments]. Nat Med 2: 467-469.
53. Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, et al. (2012) Beta-adrenergic Sweat Secretion as a Diagnostic Test for Cystic Fibrosis. American journal of respiratory and critical care medicine.
54. Schwarz V, Sutcliffe CH, (1967) The effect of some ions and drugs on sweat secretion. Bibl Paediatr 86: 89-94.
55. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, et al. (2001) Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 108: 1705-1715.
56. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, et al. (2011) The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized medicine 8: 161-173.
57. Rochon J, (1990) A statistical model for the "N-of-1" study. Journal of clinical epidemiology 43: 499-508.
58. Spiegelhalter DJ (1988) Statistical issues in studies of individual response. Scandinavian journal of gastroenterology Supplement 147: 40-45.
59. Barlow DH, Hersen M (1984) Single Case Experimental Designs MA, USA: Allyn and Bacon.
60. Kazdin AE (1982) Single-Case Research Designs: Methods for Clinical and Applied Settings. New York, USA: Oxford University Press.